142 related articles for article (PubMed ID: 36357161)
1. Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases.
Stalman EW; Wieske L; van Dam KPJ; Kummer LY; van Kempen ZLE; Killestein J; Volkers AG; Tas SW; Boekel L; Wolbink GJ; Van der Kooi AJ; Raaphorst J; Löwenberg M; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Parra Sanchez A; van Els CACM; Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart CF; Teng OYK; van Paassen P; Busch MH; Jallah PBP; Brusse E; van Doorn PA; Baars AE; Hijnen DJ; Schreurs CRG; Van der Pol WL; Goedee HS; Steenhuis M; Keijzer S; Keijser JBD; Boogaard A; Cristianawati O; Ten Brinke A; Verstegen NJM; Zwinderman KAH; Rispens T; van Ham SM; Kuijpers TW; Eftimov F;
Ann Rheum Dis; 2022 Dec; 81(12):1757-1766. PubMed ID: 36357161
[TBL] [Abstract][Full Text] [Related]
2. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies.
Boekel L; Stalman EW; Wieske L; Hooijberg F; van Dam KPJ; Besten YR; Kummer LYL; Steenhuis M; van Kempen ZLE; Killestein J; Volkers AG; Tas SW; van der Kooi AJ; Raaphorst J; Löwenberg M; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Parra Sanchez A; van Els CACM; de Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart CF; Teng YKO; van Paassen P; Busch MH; Jallah PBP; Brusse E; van Doorn PA; Baars AE; Hijnen DJ; Schreurs CRG; van der Pol WL; Goedee HS; Vogelzang EH; Leeuw M; Atiqi S; van Vollenhoven R; Gerritsen M; van der Horst-Bruinsma IE; Lems WF; Nurmohamed MT; Boers M; Keijzer S; Keijser J; van de Sandt C; Boogaard A; Cristianawati O; Ten Brinke A; Verstegen NJM; Zwinderman KAH; van Ham SM; Rispens T; Kuijpers TW; Wolbink G; Eftimov F;
Lancet Rheumatol; 2022 Jun; 4(6):e417-e429. PubMed ID: 35527808
[TBL] [Abstract][Full Text] [Related]
3. Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity.
van Dam KPJ; Volkers AG; Wieske L; Stalman EW; Kummer LYL; van Kempen ZLE; Killestein J; Tas SW; Boekel L; Wolbink GJ; van der Kooi AJ; Raaphorst J; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Sanchez AP; van Els CACM; de Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart RCF; Teng YKO; van Paassen P; Busch MH; Jallah PBP; Brusse E; van Doorn PA; Baars AE; Hijnen DJ; Schreurs CRG; van der Pol WL; Goedee HS; Steenhuis M; Keijzer S; Keijser JBD; Cristianawati O; Ten Brinke A; Verstegen NJM; van Ham SM; Rispens T; Kuijpers TW; Löwenberg M; Eftimov F;
BMC Infect Dis; 2023 May; 23(1):332. PubMed ID: 37198536
[TBL] [Abstract][Full Text] [Related]
4. Impact of immunosuppressive therapy on SARS-CoV-2 mRNA vaccine effectiveness in patients with immune-mediated inflammatory diseases: a Danish nationwide cohort study.
Elmahdi R; Ward D; Ernst MT; Poulsen G; Hallas J; Pottegård A; Jess T
BMJ Open; 2024 Feb; 14(2):e077408. PubMed ID: 38387988
[TBL] [Abstract][Full Text] [Related]
5. Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy.
Stalman EW; Wieske L; Keijser JBD; van Dam KPJ; Kummer LYL; Wilbrink MF; van Kempen ZLE; Killestein J; Volkers AG; Tas SW; Boekel L; Wolbink GJ; van der Kooi AJ; Raaphorst J; Löwenberg M; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Parra Sanchez A; van Els CACM; de Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart RCF; Onno Teng YK; van Paassen P; Busch MH; Brusse E; van Doorn PA; Baars AE; Hijnen D; Schreurs CRG; van der Pol WL; Goedee HS; Steenhuis M; Keijzer S; Cristianawati O; Brinke AT; Verstegen NJM; Zwinderman KAH; van Ham SM; Rispens T; Welkers MR; Jonges M; Eftimov F; Kuijpers TW;
J Allergy Clin Immunol; 2024 May; ():. PubMed ID: 38763170
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study - the BELCOMID study.
Geldof J; Truyens M; Sabino J; Ferrante M; Lambert J; Lapeere H; Hillary T; Van Laethem A; de Vlam K; Verschueren P; Padalko E; Lobaton T; Vermeire S
Front Immunol; 2023; 14():1126351. PubMed ID: 36936974
[TBL] [Abstract][Full Text] [Related]
7. Correlates of breakthrough Omicron (B.1.1.529) infections in a prospective cohort of vaccinated patients with rheumatic diseases.
Benny L; Mehta P; Ahmed S; Paul A; Sukumaran A; Mohanan M; Vijayan A; Kaveri K; Padmaja R; Shenoy P
Rheumatol Int; 2023 Jun; 43(6):1033-1039. PubMed ID: 37029793
[TBL] [Abstract][Full Text] [Related]
8. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.
Sormani MP; Schiavetti I; Inglese M; Carmisciano L; Laroni A; Lapucci C; Visconti V; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Cocco E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Pizzorno M; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A;
EBioMedicine; 2022 Jun; 80():104042. PubMed ID: 35526306
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis.
van Kempen ZLE; Stalman EW; Steenhuis M; Kummer LYL; van Dam KPJ; Wilbrink MF; Ten Brinke A; van Ham SM; Kuijpers T; Rispens T; Eftimov F; Wieske L; Killestein J;
J Neurol Neurosurg Psychiatry; 2023 Apr; 94(4):280-283. PubMed ID: 36564175
[TBL] [Abstract][Full Text] [Related]
10. Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS-CoV-2 in an Unvaccinated Cohort.
Simon D; Tascilar K; Kleyer A; Fagni F; Krönke G; Meder C; Dietrich P; Orlemann T; Kliem T; Mößner J; Liphardt AM; Schönau V; Bohr D; Schuster L; Hartmann F; Leppkes M; Ramming A; Pachowsky M; Schuch F; Ronneberger M; Kleinert S; Hueber AJ; Manger K; Manger B; Atreya R; Berking C; Sticherling M; Neurath MF; Schett G
Arthritis Rheumatol; 2022 May; 74(5):783-790. PubMed ID: 34951137
[TBL] [Abstract][Full Text] [Related]
11. Breakthrough SARS-CoV-2 Infections in Patients With Immune-Mediated Disease Undergoing B Cell-Depleting Therapy: A Retrospective Cohort Analysis.
Calabrese CM; Kirchner E; Husni EM; Moss BP; Fernandez AP; Jin Y; Calabrese LH
Arthritis Rheumatol; 2022 Dec; 74(12):1906-1915. PubMed ID: 35791921
[TBL] [Abstract][Full Text] [Related]
12. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study.
Wieske L; van Dam KPJ; Steenhuis M; Stalman EW; Kummer LYL; van Kempen ZLE; Killestein J; Volkers AG; Tas SW; Boekel L; Wolbink GJ; van der Kooi AJ; Raaphorst J; Löwenberg M; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Sanchez AP; van Els CACM; de Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart RCF; Teng YKO; van Paassen P; Busch MH; Jallah PBP; Brusse E; van Doorn PA; Baars AE; Hijnen DJ; Schreurs CRG; van der Pol WL; Goedee HS; Keijzer S; Keijser JBD; Boogaard A; Cristianawati O; Ten Brinke A; Verstegen NJM; Zwinderman KAH; van Ham SM; Kuijpers TW; Rispens T; Eftimov F;
Lancet Rheumatol; 2022 May; 4(5):e338-e350. PubMed ID: 35317410
[TBL] [Abstract][Full Text] [Related]
13. Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases.
Wieske L; Kummer LYL; van Dam KPJ; Stalman EW; van der Kooi AJ; Raaphorst J; Löwenberg M; Takkenberg RB; Volkers AG; D'Haens GRAM; Tas SW; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Killestein J; van Kempen ZLE; Voskuyl AE; Broens B; Sanchez AP; Wolbink G; Boekel L; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart CF; Teng YKO; van Paassen P; Busch MH; Jallah BP; Brusse E; van Doorn PA; Baars AE; Hijnen D; Schreurs CRG; van der Pol WL; Goedee HS; Steenhuis M; Rispens T; Ten Brinke A; Verstegen NJM; Zwinderman KAH; van Ham SM; Kuijpers TW; Eftimov F;
BMC Med; 2022 Mar; 20(1):100. PubMed ID: 35236350
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey.
Hoff LS; Ravichandran N; Shinjo SK; Day J; Sen P; Junior JG; Lilleker JB; Joshi M; Agarwal V; Kardes S; Kim M; Milchert M; Makol A; Gheita T; Salim B; Velikova T; Gracia-Ramos AE; Parodis I; O'Callaghan AS; Nikiphorou E; Tan AL; Chatterjee T; Cavagna L; Saavedra MA; Ziade N; Knitza J; Kuwana M; Nune A; Distler O; Cansu DÜ; Traboco L; Wibowo SAK; Tehozol EAZ; Serrano JR; La Torre IG; Wincup C; Pauling JD; Chinoy H; Agarwal V; Aggarwal R; Gupta L;
Rheumatol Int; 2023 Jan; 43(1):47-58. PubMed ID: 36271958
[TBL] [Abstract][Full Text] [Related]
15. A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center.
Sarmiento-Monroy JC; Espinosa G; Londoño MC; Meira F; Caballol B; Llufriu S; Carrasco JL; Moll-Udina A; Quintana LF; Giavedoni P; Ramírez J; Inciarte-Mundo J; Solana E; Blanco Y; Martinez-Hernandez E; Sepúlveda M; Llorenç V; Prieto-González S; Espígol-Frigolé G; Milisenda JC; Cid MC; Mascaró JM; Blanco I; Barberá JA; Sibila O; Gratacos-Ginès J; Adán A; Agustí A; Sanmartí R; Panés J; Cervera R; Vila J; Soriano A; Gómez-Puerta JA;
J Autoimmun; 2021 Feb; 117():102580. PubMed ID: 33338707
[TBL] [Abstract][Full Text] [Related]
16. Effect of Third and Fourth mRNA-Based Booster Vaccinations on SARS-CoV-2 Neutralizing Antibody Titer Formation, Risk Factors for Non-Response, and Outcome after SARS-CoV-2 Omicron Breakthrough Infections in Patients on Chronic Hemodialysis: A Prospective Multicenter Cohort Study.
Tillmann FP; Figiel L; Ricken J; Still H; Korte C; Plaßmann G; Harth A; Jörres A; von Landenberg P
J Clin Med; 2022 Jun; 11(11):. PubMed ID: 35683580
[TBL] [Abstract][Full Text] [Related]
17. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients.
Piñana JL; Vazquez L; Calabuig M; López-Corral L; Martin-Martin G; Villalon L; Sanz-Linares G; Conesa-Garcia V; Sanchez-Salinas A; Gago B; Facal A; Risco-Gálvez I; Olave MT; Espigado I; Lopez-Jimenez J; Hernández-Rivas JÁ; Avendaño-Pita A; Arroyo I; Ferrer E; García-Cadenas I; González-Santillana C; Roldán-Pérez A; Ferrer B; Guerreiro M; Suarez-Lledó M; Camara A; Campos-Beltrán D; Navarro D; Cedillo Á; Sureda A; Solano C; ; Martino R
Blood Cancer J; 2023 Jan; 13(1):8. PubMed ID: 36599843
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy.
Syversen SW; Jyssum I; Tveter AT; Sexton J; Christensen IE; Tran TT; Bjørlykke KH; Mjaaland S; Warren DJ; Kvien TK; Chopra A; Kro GB; Jahnsen J; Munthe LA; Haavardsholm EA; Grødeland G; Vaage JT; Provan SA; Jørgensen KK; Goll GL
RMD Open; 2022 Nov; 8(2):. PubMed ID: 36328399
[TBL] [Abstract][Full Text] [Related]
19. Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections.
Stærke NB; Reekie J; Nielsen H; Benfield T; Wiese L; Knudsen LS; Iversen MB; Iversen K; Fogh K; Bodilsen J; Juhl MR; Lindvig SO; Øvrehus A; Madsen LW; Klastrup V; Andersen SD; Juhl AK; Andreasen SR; Ostrowski SR; Erikstrup C; Fischer TK; Tolstrup M; Østergaard L; Johansen IS; Lundgren J; Søgaard OS
Nat Commun; 2022 Aug; 13(1):4466. PubMed ID: 35915081
[TBL] [Abstract][Full Text] [Related]
20. Timely course of SARS-CoV-2 infections and vaccinations in patients with hemato-oncological diseases: analysis of a real-life cohort.
Mair MJ; Mitterer M; Buratti T; Berchtold L; Fong D; Preusser M
ESMO Open; 2023 Jun; 8(3):101559. PubMed ID: 37196399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
